Highlights
- Moderna’s COVID-19 vaccine suspended in some counties for younger adults due to some rare side effects.
- Sweden, Norway, and Denmark paused Moderna’s COVID-19 vaccine and urged younger adults to take Pfizer/BioNTech shot.
- On 5 October, the European regulator approved the booster shot of Moderna’s COVID-19 vaccine for 12 years or older people.
Few European nations have temporary banned Moderna Inc’s (NASDAQ:MRNA) COVID-19 vaccine in younger adults after appearance of some rare heart related side effects especially after the second shot. Following the suspension news, Moderna’s shares fell as much as 8.94% on 6 October 2021 on NASDAQ.
In January 2021, the European Medicines Agency (EMA) gave green light to Moderna’s COVID-19 vaccine for people 18 years and over. In July, the vaccine was given emergency use authorisation for children aged 12-17 year.
Scandinavian agencies suspend Moderna’s vaccine
On 6 October 2021, Scandinavian authorities halted administration of COVID-19 vaccine of Moderna in young adults due to an increased risk of inflammation of the heart muscle.
The Public Health Agency of Sweden had terminated Moderna’s COVID-19 vaccine for those individuals under 30 years. The agency highlighted that the temporary halt would be initially in force until 1 December 2021.
Furthermore, the agency highlighted that, the risk is more prevalent among young men and boys and seems especially related to the second shot of the vaccine.
RELATED ARTICLE: Tips for investing in COVID-19 vaccines developing stocks
Source: © Ekahardiwito | Megapixl.com
Norway and Denmark to continue using Pfizer/BioNTech vaccine
Norway and Denmark also recommended a halt for people under 18 years. Denmark highlighted that the country will continue to use the vaccine developed by Pfizer-BioNTech as its main choice for people aged 12-17 years. Besides, Norway urged people who are under 30 to get the Pfizer-BioNTech’s vaccine instead.
The COVID-19 vaccines developed by Moderna and Pfizer-BioNTech rely on messenger RNA (mRNA) technology to induce an immune reaction against novel coronavirus.
RELATED READ: Role of mRNA vaccines in combating COVID-19: Pros & Cons
Moderna’s booster shot got EMA green light
On 5 October 2021, the European Medicines Agency (EMA) approved the use of a booster shot or third dose of Moderna COVID-19 vaccine for people (12 years of age or older) having severely deteriorated immune system. Moderna highlighted that several studies have demonstrated the benefit of a booster shot of COVID-19 vaccine in people having compromised immune system.
RELATED READ: COVID-19 booster shot for immunocompromised people: are there any additional risks?
Source: © Demidovichphotostock | Megapixl.com
Bottom Line
After witnessing the heart related side effects post administration of Moderna’s COVID-19 vaccine in younger adults, selected European nations have recommended to use Pfizer-BioNTech’s COVID-19 vaccine for adults under 30 year.
.png "How rebalancing an investment portfolio can help in uncertain times?")
.png "How to prepare for market volatility ahead of elections?")
.png "Will The Recent Housing Policy Be A Game Changer for the Liberal Party?")
.png "How to innovate and excel in entrepreneurial journey? | Expert talk with Steve Dalton & Daniel Evans")
.png "How did these ASX blue-chip stocks perform?")
.png "Crypto Analyst Believes that collapse of Tether is now imminent")
.png "ASX Falls; JB HI-FI Is The Top Loser")
Be the First to Comment